Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Menarini and OBT Sign Major Strategic Collaboration

Published: Tuesday, October 30, 2012
Last Updated: Tuesday, October 30, 2012
Bookmark and Share
Strategic alliance for the clinical development and manufacture of a portfolio of novel antibody-based cancer drugs.

Menarini and Oxford BioTherapeutics (OBT) have announced a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.

The agreement covers five of OBT’s antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via a different novel oncology target.

The deal brings together OBT’s discovery expertise with Menarini’s clinical knowledge, and expanding capabilities in the manufacture and development of biologics, to build value for both companies as they work to bring this exciting portfolio of next generation antibody-based cancer drugs to market.

Under the collaboration, Menarini will lead the efforts in the manufacture and clinical development of each program, supported by OBT, while OBT will provide the proprietary cancer target, antibody and arming technologies.

Once clinical proof of concept has been achieved, OBT will complete the clinical development and commercialize these novel antibody-based products in North America and Japan, whilst Menarini will develop and commercialize the products in Europe, CIS, Asia and Latin America.

Christian Rohlff, CEO of OBT, commented, “I am delighted to collaborate with Menarini, a company that has made impressive achievements in biologics development and demonstrated an enduring commitment to the development of innovative cancer therapies. This creative alliance is transformational for us as it allows OBT to participate in the clinical development and future commercialization of our programs while at the same time it bolsters Menarini’s pipeline with a portfolio of the next generation of cancer drugs. We believe this innovative business framework could become the business model of choice for rapidly growing biotechnology companies seeking new ways to develop their drug pipeline effectively.”

Alberto Giovanni Aleotti, member of the Board of A. Menarini, commented, “We are eager to start our collaboration with OBT, an oncology company with a proven track record of generating innovative antibody-based cancer drug candidates that are designed to address high unmet medical needs. I am very pleased that this novel strategic alliance, which foresees the development and manufacture of up to 5 cancer treatment programs and a total investment of 800 million Euro, will enable us to further demonstrate our deep and long standing commitment to the fight against cancer, which has always been crucial to Menarini’s overall corporate mission.”

OBT’s dedicated development operation in Basel, Switzerland, established in May 2012 under the direction of COO Dr. Esteban Pombo, will perform a central role in supporting the new collaboration as OBT and Menarini work together to progress OBT’s most advanced therapeutic antibody and antibody drug conjugate (ADC) oncology programs into clinical development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford BioTherapeutics Appoints Dr Eugen Leo
Dr. Leo will be responsible for driving the Company’s pipeline of ADCs into clinical development.
Thursday, July 10, 2014
Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology
Company to develop novel antibody-drug conjugate for HER2-negative breast cancer.
Friday, May 16, 2014
OBT and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia
First clinical development candidate in $1 billion oncology investment alliance.
Thursday, January 02, 2014
OBT and Boehringer Ingelheim Enter Collaboration
Collaboration to discover novel antibody targets in cancer.
Monday, April 29, 2013
Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™
Agreement covers the research, development and commercial use of the GS System™ by Oxford BioTherapeutics.
Monday, September 05, 2011
Scientific News
New Mechanism to Control Human Viral Infections Discovered
Researchers discover long sought after mechanism in human cells that could help treat diseases caused by viruses.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
RNAi Activated in Response to Influenza
Discovery could lead to better ways of combating serious infections, including Ebola and Zika.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
New Strategy May Drop Cancer’s Guard
Scientists eye ways to deconstruct tumors’ protective wall with current diabetes drug.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Smart Patch Releases Blood Thinners When Needed
Researchers have developed a smart patch that activelly monitors a patient's blood and releases blood thinning drugs when necessary.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!